The intensive care medicine research agenda on septic shock

[1]  P. Marik,et al.  Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before‐After Study , 2017, Chest.

[2]  J. Singer,et al.  The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience* , 2017, Critical care medicine.

[3]  Matthew M Churpek,et al.  Identifying Patients With Sepsis on the Hospital Wards , 2017, Chest.

[4]  Michael Bailey,et al.  Early, Goal‐Directed Therapy for Septic Shock — A Patient‐Level Meta‐Analysis , 2017, The New England journal of medicine.

[5]  M. Shankar-Hari,et al.  The use of enrichment to reduce statistically indeterminate or negative trials in critical care , 2017, Anaesthesia.

[6]  Sangeeta Mehta,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 , 2017, Intensive Care Medicine.

[7]  Alan E. Jones,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 , 2017, Intensive Care Medicine.

[8]  S. Yende,et al.  Proportion and Cost of Unplanned 30-Day Readmissions After Sepsis Compared With Other Medical Conditions , 2017, JAMA.

[9]  M. Vollmer,et al.  Quality Improvement Initiative for Severe Sepsis and Septic Shock Reduces 90-Day Mortality: A 7.5-Year Observational Study* , 2017, Critical care medicine.

[10]  J. Wetterslev,et al.  Higher vs. lower haemoglobin threshold for transfusion in septic shock: subgroup analyses of the TRISS trial , 2017, Acta anaesthesiologica Scandinavica.

[11]  K. Famous,et al.  Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy , 2016, American journal of respiratory and critical care medicine.

[12]  M. Filbin,et al.  A Administration of Emergency Medicine NEW MANDATED CENTERS FOR MEDICARE AND MEDICAID SERVICES REQUIREMENTS FOR SEPSIS REPORTING : CAUTION FROM THE FIELD , 2016 .

[13]  F. Lamontagne,et al.  Understanding patient-centredness: contrasting expert versus patient perspectives on vasopressor therapy for shock , 2017, Intensive Care Medicine.

[14]  M. Shankar-Hari,et al.  Differences in Impact of Definitional Elements on Mortality Precludes International Comparisons of Sepsis Epidemiology—A Cohort Study Illustrating the Need for Standardized Reporting* , 2016, Critical care medicine.

[15]  M. Singer,et al.  Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. , 2016, JAMA.

[16]  R. Bellomo,et al.  Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy , 2016, Intensive Care Medicine.

[17]  Jørn Wetterslev,et al.  Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial , 2016, Intensive Care Medicine.

[18]  Arthur S Slutsky,et al.  The RECOVER Program: Disability Risk Groups and 1-Year Outcome after 7 or More Days of Mechanical Ventilation. , 2016, American journal of respiratory and critical care medicine.

[19]  J. Wernerman,et al.  Long-term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial , 2016, Intensive Care Medicine.

[20]  L. Prosser,et al.  Caregivers and Families of Critically Ill Patients. , 2016, The New England journal of medicine.

[21]  I. Bygbjerg,et al.  Caregivers and Families of Critically Ill Patients. , 2016, The New England journal of medicine.

[22]  S. Pocock,et al.  The Primary Outcome Is Positive - Is That Good Enough? , 2016, The New England journal of medicine.

[23]  Stuart J Pocock,et al.  The Primary Outcome Fails - What Next? , 2016, The New England journal of medicine.

[24]  G. Perkins,et al.  Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. , 2016, JAMA.

[25]  Derek C Angus,et al.  Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design. , 2016, American journal of respiratory and critical care medicine.

[26]  C. Fjell,et al.  Plasma cytokine levels predict response to corticosteroids in septic shock , 2016, Intensive Care Medicine.

[27]  Anna Rautanen,et al.  Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study , 2016, The Lancet. Respiratory medicine.

[28]  R. Bellomo,et al.  Is the literature inconclusive about the harm from HES? No , 2016, Intensive Care Medicine.

[29]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[30]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[31]  T. Rea,et al.  Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[32]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[33]  Sangeeta Mehta,et al.  Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial , 2016, Intensive Care Medicine.

[34]  F. Taccone,et al.  Understanding PK/PD , 2016, Intensive Care Medicine.

[35]  V. Rai,et al.  Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis , 2016, Intensive Care Medicine.

[36]  J. Selby,et al.  Stakeholder-Driven Comparative Effectiveness Research: An Update From PCORI. , 2015, JAMA.

[37]  James F Burke,et al.  Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care. , 2015, American journal of respiratory and critical care medicine.

[38]  P. Kirchhof,et al.  Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data , 2015, BMJ : British Medical Journal.

[39]  M. Puskarich,et al.  The Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock: A Systematic Review and Meta-Analysis* , 2015, Critical care medicine.

[40]  Derek C Angus,et al.  Fusing Randomized Trials With Big Data: The Key to Self-learning Health Care Systems? , 2015, JAMA.

[41]  D. Dongelmans,et al.  What are effective strategies for the implementation of care bundles on ICUs: a systematic review , 2015, Implementation Science.

[42]  Francesco Santini,et al.  Mortality in Multicenter Critical Care Trials: An Analysis of Interventions With a Significant Effect* , 2015, Critical care medicine.

[43]  Cheng Cheng Tan,et al.  The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study) , 2015, Intensive Care Medicine.

[44]  David T. Huang,et al.  A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators , 2015, Intensive Care Medicine.

[45]  S. Opal,et al.  Sepsis: a roadmap for future research. , 2015, The Lancet. Infectious diseases.

[46]  E. de Jonge,et al.  The association between time to antibiotics and relevant clinical outcomes in emergency department patients with various stages of sepsis: a prospective multi-center study , 2015, Critical Care.

[47]  Derek Bell,et al.  Trial of early, goal-directed resuscitation for septic shock. , 2015, The New England journal of medicine.

[48]  R. Hotchkiss,et al.  Getting sepsis therapy right , 2015, Science.

[49]  Ilias Tagkopoulos,et al.  From Data to Optimal Decision Making: A Data-Driven, Probabilistic Machine Learning Approach to Decision Support for Patients With Sepsis , 2015, JMIR medical informatics.

[50]  C. Lindsell,et al.  Developing a clinically feasible personalized medicine approach to pediatric septic shock. , 2015, American journal of respiratory and critical care medicine.

[51]  S. Lemeshow,et al.  Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. , 2015, Critical care medicine.

[52]  M. Matthay,et al.  Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. , 2014, The Lancet. Respiratory medicine.

[53]  N. Zhong,et al.  Compliance with severe sepsis bundles and its effect on patient outcomes of severe community-acquired pneumonia in a limited resources country , 2014, Archives of medical science : AMS.

[54]  Michael Bailey,et al.  Goal-directed resuscitation for patients with early septic shock. , 2014, The New England journal of medicine.

[55]  M. Reilly,et al.  PCSK9 is a critical regulator of the innate immune response and septic shock outcome , 2014, Science Translational Medicine.

[56]  V. Pettilä,et al.  Lower versus higher hemoglobin threshold for transfusion in septic shock. , 2014, The New England journal of medicine.

[57]  L. Chawla,et al.  Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study , 2014, Critical Care.

[58]  Theodore J Iwashyna,et al.  What's so different about big data?. A primer for clinicians trained to think epidemiologically. , 2014, Annals of the American Thoracic Society.

[59]  Dylan S. Small,et al.  Outcomes and statistical power in adult critical care randomized trials. , 2014, American journal of respiratory and critical care medicine.

[60]  J. Tenhunen,et al.  Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer’s acetate , 2014, Intensive Care Medicine.

[61]  Amber E Barnato,et al.  A randomized trial of protocol-based care for early septic shock. , 2014, The New England journal of medicine.

[62]  Claude Guerin,et al.  High versus low blood-pressure target in patients with septic shock. , 2014, The New England journal of medicine.

[63]  R. Bellomo,et al.  Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. , 2014, JAMA.

[64]  R. Bellomo,et al.  Hydroxyethyl starch: putting patient safety first , 2014, Intensive Care Medicine.

[65]  F. Machado,et al.  Implementation of a multifaceted sepsis education program in an emerging country setting: clinical outcomes and cost-effectiveness in a long-term follow-up study , 2014, Intensive Care Medicine.

[66]  M. Singer,et al.  Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. , 2013, JAMA.

[67]  Y. K. Jeong,et al.  The adverse effect of emergency department crowding on compliance with the resuscitation bundle in the management of severe sepsis and septic shock , 2013, Critical Care.

[68]  J. Wetterslev,et al.  Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial , 2013, Intensive Care Medicine.

[69]  David T. Huang,et al.  Harmonizing international trials of early goal-directed resuscitation for severe sepsis and septic shock: methodology of ProCESS, ARISE, and ProMISe , 2013, Intensive Care Medicine.

[70]  R. Bellomo,et al.  The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock. , 2013, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[71]  A. Costa-Pereira,et al.  Differences in compliance with Surviving Sepsis Campaign recommendations according to hospital entrance time: day versus night , 2013, Critical Care.

[72]  R. Hotchkiss,et al.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. , 2013, The Lancet. Infectious diseases.

[73]  Dean A Fergusson,et al.  Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. , 2013, JAMA.

[74]  M. Murphy,et al.  Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis , 2013, British journal of anaesthesia.

[75]  Brad Spellberg,et al.  The future of antibiotics and resistance. , 2013, The New England journal of medicine.

[76]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[77]  R. Bellomo,et al.  Hydroxyethyl starch or saline for fluid resuscitation in intensive care. , 2012, The New England journal of medicine.

[78]  R. Sawyer,et al.  Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. , 2012, The Lancet. Infectious diseases.

[79]  Ethan M Balk,et al.  Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials , 2012, Annals of Internal Medicine.

[80]  J. Tenhunen,et al.  Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. , 2012, The New England journal of medicine.

[81]  Andrew Rhodes,et al.  Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.

[82]  Isabelle Boutron,et al.  Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study , 2012, BMJ : British Medical Journal.

[83]  Sergio Sismondo,et al.  Industry sponsorship and research outcome. , 2012, The Cochrane database of systematic reviews.

[84]  Derek C Angus,et al.  The search for effective therapy for sepsis: back to the drawing board? , 2011, JAMA.

[85]  K. Maitland,et al.  Mortality after fluid bolus in African children with severe infection. , 2011, The New England journal of medicine.

[86]  P. Barie,et al.  Unblinding plan of PROWESS-SHOCK trial , 2011, Intensive Care Medicine.

[87]  Cheng Cheng Tan,et al.  Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study , 2011, BMJ : British Medical Journal.

[88]  Rachel F. Eyler,et al.  Antibiotic dosing in critically ill patients with acute kidney injury , 2011, Nature Reviews Nephrology.

[89]  A. Day,et al.  Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials , 2011, Critical care.

[90]  Taka-aki Nakada,et al.  Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality* , 2011, Critical care medicine.

[91]  K. Walley,et al.  beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. , 2010, American journal of respiratory and critical care medicine.

[92]  T. Mäkikallio,et al.  Insertion/deletion polymorphism in alpha2-adrenergic receptor gene is a genetic risk factor for sudden cardiac death. , 2009, American heart journal.

[93]  R. Favory,et al.  Carbon Monoxide Rescues Mice from Lethal Sepsis by Supporting Mitochondrial Energetic Metabolism and Activating Mitochondrial Biogenesis , 2009, Journal of Pharmacology and Experimental Therapeutics.

[94]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[95]  Sangeeta Mehta,et al.  Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.

[96]  Jessina C. McGregor,et al.  A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  M. Revel,et al.  Comparison of two fluid-management strategies in acute lung injury, H.P. Wiedemann, A.P. Wheeler, G.R. Bernard, B.T. Thompson, D. Hayden, B. deBoisblanc, A.F Jr. Connors, R.D. Hite, A.L. Harabin, in: N Engl J Med, 354. (2006), 2564 , 2007 .

[98]  Gordon R Bernard,et al.  Comparison of two fluid-management strategies in acute lung injury. , 2006, The New England journal of medicine.

[99]  G. Guyatt,et al.  Validity of composite end points in clinical trials , 2005, BMJ : British Medical Journal.

[100]  Margaret M Parker,et al.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.

[101]  John Land,et al.  Association between mitochondrial dysfunction and severity and outcome of septic shock , 2002, The Lancet.

[102]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[103]  R. Kim,et al.  The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. , 2001, The New England journal of medicine.

[104]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[105]  J. Vincent,et al.  Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study , 2001, Critical care medicine.

[106]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[107]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[108]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.